mRNA Vaccine and Therapeutics Market 2021-26: Industry Growth, Size, Share, Analysis and Forecast
By: IMARC Group
The messenger ribonucleic acid, or mRNA, refers to a protein-coding gene in the genome that provides a basis for protein synthesis within the cells. The mRNA vaccines and therapeutics include self-amplifying, in-vivo self-replicating, and in-vitro dendritic cell non-replicating mRNA that combine the desirable immunological properties. These vaccines are usually injected into the body to trigger virus-detecting immune sensors and produce viral antigen protein cells, which aid in enhancing the immunity of the body by improving B- and T- cell responses.
The mRNA vaccines are more effective against pathogens, cost-efficient, and have enhanced immunogenicity and higher potency. As a result, leading players are focusing on the development of an mRNA-based vaccine for the coronavirus disease (COVID-19). The success of the vaccine for COVID-19 can potentially boost the market growth. Along with this, improvements in healthcare technologies, such as the development of lipid nanoparticle formulations for in-vivo systemic delivery of mRNA, is providing a positive impact on the industry.
Request Free Sample Report: https://www.imarcgroup.com/
List of Key Companies Covered in this Market Report:
The report has segmented the market on the basis of vaccine type, treatment type, vaccine manufacturing, application, end-user and geography.
Breakup by Vaccine Type:
Breakup by Treatment Type:
Breakup by Vaccine Manufacturing:
Breakup by Application:
Breakup by End-User:
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-